OpSens Announces Record Revenue for Second Quarter Fiscal 2023

Quebec City, Quebec, April 13, 2023 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today reported its results for the second quarter of fiscal year 2023, ended February 28, 2023.

Second Quarter Fiscal 2023 Financial Highlights (all metrics compared to second quarter fiscal 2022 unless otherwise noted)

  • Consolidated revenues of $10.8 million, compared with $8.1 million, a 33% increase and a new quarterly record.
  • Gross margin improved to 56.9% in the second quarter of 2023 compared with 51.5%.
  • Coronary artery disease sales of $5.7 million in the second quarter of 2023 compared with $4.6 million, a 23% increase.
  • Structural Heart sales of $0.5 million in the second quarter of 2023, driven by a 31% sequential increase in sales as compared to the first quarter of 2023.
  • Sales of optical medical products were $3.4 million in the second quarter of 2023, an increase of 43%, compared with $2.4 million.
  • Cash and cash equivalents of $21.9 million at February 28, 2023 ($17.5 million at November 30, 2022).
  • In December 2022, the Company closed a public bought deal offering for aggregate gross proceeds of $11.5 million.

Recent Highlights

  • SavvyWire used during two live cases at CRT Conference.
  • Awarded interventional specialty diagnostics agreement with Premier for SavvyWire.
  • Appointed John Hannigan as Chief Financial Officer.

Management Commentary

“I am pleased with the results of the quarter, which reflect record quarterly revenues, driven by 38% growth in our medical segment as we expand worldwide adoption of the OptoWire, continue with our strategic launch of SavvyWire and benefit from the increased demand in optical sensors for business partnerships” said Louis Laflamme, President and CEO of OpSens. “We continue to make significant progress for our proprietary devices, with OptoWire sales up 30% in the U.S. compared to quarter two 2022 and SavvyWire sales increasing 31% on quarter one fiscal year 2023.  Our sales team continues to highlight the unique benefits of our solutions in terms of contributing to improving clinical workflows and results for patients.  Following FDA clearance and the current controlled market release for SavvyWire, we are now ramping up our commercialization of this revolutionary concept in Structural Heart. This, along with our new GPO agreement, provides a solid platform for our next stage of commercialization to drive continuous incremental growth in the coming quarters.”

Segmented Revenues Information

($ in Millions Canadian)

Three-month period ended Feb. 28, 2023

  Three-month period ended Feb. 28, 2022   Six-month   period ended Feb. 28, 2023  

Six-month   period ended Feb. 28, 2023

               
Medical segment              
Coronary Artery Disease

5.7

  4.6   10.9  

9.5

Structural Heart

0.5

  0.0   0.9  

0.0

Optical Medical Products

3.4

  2.4   6.7  

4.8

Other

0.3

  0.1   0.6  

0.1

Total Medical Revenues

9.9

  7.1   19.1  

14.5

Industrial

0.9

  1.0   1.9  

1.7

Total Revenues

10.8

  8.1   21.0  

16.2

Financial Commentary

Consolidated revenues were $10.8 million in the second quarter of 2023, a 33% increase, compared with the $8.1 million recorded in the second quarter of 2022.

Coronary Artery Disease

Sales of coronary artery disease products (Fractional Flow Reserve (“FFR”) and diastolic pressure ratio (“dPR”)) were $5.7 million in the second quarter of 2023, compared with $4.6 million in the second quarter of 2022, an increase of 23%. The combination of OptoWire and SavvyWire in North America contributed to enhanced performance with a 24% increase.  For EMEA and Asia Pacific, markets served through distributors, growth has been 13% despite some headwinds including currency exchange rates.

Optical Medical Systems

Sales of optical medical systems, including the Company’s multi-year supply contract of sensors for ventricular assist devices, were $3.4 million in the second quarter of 2023, compared with $2.4 million in the second quarter of 2022, an increase of 43%. The Company is seeing increased demand for its sensors with expectations for continued growth in the future.

Structural Heart

Structural heart sales, despite being in controlled release in the U.S. market, were $0.5 million in the second quarter of 2023, driven by a 31% sequential increase in sales as compared to the first quarter of 2023.  There were no sales in this market in the second quarter of 2022.   Initial results are indicating steady acceptance by physicians and hospitals with premium pricing. Furthermore, we are seeing some commonality in terms of customers who are using both SavvyWire and OptoWire products. This aligns with our commercial strategy.

Industrial

Industrial sales were at $0.9 million in the second quarter of 2023, compared with $1.0 million in the second quarter of 2022. During the quarter, the Company delivered solutions in optical temperature, pressure, strain, and other critical parameters for various industries, including aerospace, nuclear and power electronics.

Gross Margin

Gross margin was 56.9%, compared to 51.5% during the prior year period. The increase was driven by favorable product mix, a higher weighting of direct sales to hospitals and higher sales volume.

Operating Expenses

Operating expenses in the second quarter of 2023 were $9.3 million, compared with $6.4 million in the second quarter of 2022. The $2.9 million increase was primarily due to an increase in Sales and Marketing activities, including an increase in the Company’s direct U.S. sales force to enable the launch of SavvyWire. Research and Development expenditure increased due to structural heart and coronary artery projects.

Net Loss

Net loss for the second quarter of fiscal 2023 was $(3.0) million, or $(0.03) per diluted share, compared to a net loss of $(2.4) million, or $(0.02) per diluted share in the second quarter of fiscal 2022.

Balance Sheet

OpSens had a cash position of $21.9 million at February 28, 2023 (November 30, 2022, was $17.5 million). In December 2022, the Company closed a $11.5 million bought-deal offering.

Table A

(In thousands of Canadian dollars, except for information per share)

 

 

Three-month

period ended

Feb. 28, 2023

Three-month

 

period ended

Feb. 28, 2022

Six-month

 

period ended

Feb. 28, 2023

Six-month

period ended

Feb 28, 2022

$

$ $

$

         
Revenues        
  Sales        
       Medical

9,820

6,967 18,714

14,308

       Industrial

894

1,017 1,911 1,722
  10,714 7,984 20,625

16,030

  Other

95

116 378 165
  10,809 8,100 21,003

16,195

Cost of sales

4,658

3,930 8,985

7,908

Gross margin

6,151

4,170 12,018

8,287

Gross margin percentage

57%

51% 57%

51%

         
Operating expenses        
     Administrative

2,430

1,927 5,030

4,064

     Sales and marketing

4,390

2,490 9,018

4,598

     R&D

2,486

2,026 4,954

3,792

 

9,306

6,443 19,002

12,454

         
Financial (income) expenses

(33)

77 (40)

236

(Gain) loss on foreign currency translation

(163)

47 (358)

57

         
Loss before income taxes

(2,959)

(2,397) (6,586)

(4,460)

         
Current income tax expense

18

7 29

34

         
Net loss

(2,977)

(2,404) (6,615)

(4,494)

         
Basic and diluted net loss per share

(0.03)

(0.02) (0.06)

(0.04)

         

Table B

CONSOLIDATED BALANCE SHEET HIGHLIGHTS

 

(in thousands of Canadian dollars)

As at

As at
Feb. 28, 2023 Aug 31, 2022
$

$

     
Cash and cash equivalents

21,935

23,816

Trade and other receivables

6,907

5,855

Inventories

10,711

6,672

Total Current Assets

41,876

39,016

Property, plant, and equipment

3,254

2,683

Intangible assets

1,689

1,786

Right-of-use assets

8,250

5,026

Total Assets

55,069

 48,511

     
Current liabilities

7,616

8,601

Long-term debt

400

639

Lease liabilities

8,340

5,012

Total Liabilities

16,356

14,252

Shareholders’ equity

38,713

34,259

Conference Call Today

Louis Laflamme, President and Chief Executive Officer and John Hannigan, recently appointed Chief Financial Officer, will hold a conference call to discuss the quarter’s financial results at 11:00 a.m. (Eastern Time) today, April 13, 2023.

Interested parties can access the conference call by dialing (833) 756-0865 or (412) 317-5754 or can listen via a live webcast, from the link available in the Investors section of the Company’s website at https://opsensmedical.com/ or at  https://app.webinar.net/Xz9d83makB1, 5 to 10 minutes before the beginning of the conference call.

A replay will be available after the call, in the Investors section of the Company’s website at https://opsensmedical.com/.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    OpSens Medical. (2024, February 08). OpSens Announces Record Revenue for Second Quarter Fiscal 2023. AZoSensors. Retrieved on May 20, 2024 from https://www.azosensors.com/news.aspx?newsID=15441.

  • MLA

    OpSens Medical. "OpSens Announces Record Revenue for Second Quarter Fiscal 2023". AZoSensors. 20 May 2024. <https://www.azosensors.com/news.aspx?newsID=15441>.

  • Chicago

    OpSens Medical. "OpSens Announces Record Revenue for Second Quarter Fiscal 2023". AZoSensors. https://www.azosensors.com/news.aspx?newsID=15441. (accessed May 20, 2024).

  • Harvard

    OpSens Medical. 2024. OpSens Announces Record Revenue for Second Quarter Fiscal 2023. AZoSensors, viewed 20 May 2024, https://www.azosensors.com/news.aspx?newsID=15441.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.